| Project/Area Number |
26860320
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Immunology
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
Hashimoto Noboru 名古屋大学, 医学(系)研究科(研究院), 研究機関研究員 (90712365)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 糖鎖 / 癌 / 免疫 / 免疫監視機構 / 質量分析 / シアル酸 |
|---|
| Outline of Final Research Achievements |
Siglec-7 is an inhibitory receptor expressed on NK cells and monocytes and transduces inhibitory signals into immune cells by binding to its ligands. Although a few ligands have been reported, specificity of Siglec-7-recognized structures has not been clarified. To solve this issue, we established several sialyltransferase-transfectants that showed definite binding of Siglec-7-Fc using a human colon cancer cell line. By using the transfectants, we clarified o-glycan is a new ligand of Siglec-7. While NK cells showed high cytotoxic activity toward the parent cells, reduced cytotoxicity was observed for the transfectants. In addition, ITIM of Siglec-7 was strongly phosphorylated in the transfectants. As for the transfectants, Siglec-7-binding enhanced cell migration. Taken together, we suggest that interaction between Siglec-7 and O-glycan enable cancer cells to escape from immunosurveillance by suppression of immune cells and enhancement of cancer malignancy.
|
